Kiliç Raif, Güzel Tuncay, Aktan Adem, Güzel Hamdullah, Kaya Ahmet Ferhat, Çankaya Yusuf
Department of Cardiology, Çermik State Hospital.
Department of Cardiology, Health Science University, Gazi Yaşargil Training and Research Hospital, Diyarbakir.
Coron Artery Dis. 2025 Jan 1;36(1):39-44. doi: 10.1097/MCA.0000000000001415. Epub 2024 Dec 4.
The HALP score, measured based on hemoglobin, albumin, lymphocyte, and platelet levels, is regarded as a novel scoring system that indicates the status of systemic inflammation and nutritional health. Our study aimed to evaluate the relationship between HALP score and prognosis in non-ST-elevation myocardial infarction (NSTEMI) patients.
Between 1 January 2020 and 1 January 2022, 568 consecutive patients diagnosed with NSTEMI from a single center were included in the study retrospectively. The patients were divided into two equal groups according to the median HALP cutoff value of 44.05. Patients were followed for at least 1 year from the date of admission.
The average age of the patients was 62.3 ± 10.6 years and 43.7% were female. In-hospital and 1-year mortality were found to be significantly higher in the group with low HALP scores (6.0 vs. 2.1%, P = 0.019 and 22.5 vs. 9.9%, P < 0.001, respectively). In receiver operating characteristic curve analysis, a cutoff level of 34.6 of the HALP score predicted 1-year mortality with 71% sensitivity and 65% specificity (area under the curve: 0.707, 95% confidence interval: 0.651-0.762, P < 0.001). In Kaplan-Meier analysis, higher mortality rates were observed over time in the group with lower HALP scores (log-rank test=16.767, P < 0.001). In Cox regression analysis, the HALP score was found to be an independent predictor of 1-year mortality (odds ratio: 0.969, 95% confidence interval: 0.958-0.981, P < 0.001).
We found that a low HALP score could predict in-hospital and 1-year mortality in patients admitted to the hospital with a diagnosis of NSTEMI.
基于血红蛋白、白蛋白、淋巴细胞和血小板水平测量的HALP评分，被视为一种表明全身炎症和营养健康状况的新型评分系统。我们的研究旨在评估HALP评分与非ST段抬高型心肌梗死（NSTEMI）患者预后之间的关系。
回顾性纳入2020年1月1日至2022年1月1日期间在单一中心连续诊断为NSTEMI的568例患者。根据HALP中位数临界值44.05将患者分为两组，每组人数相等。从入院日期起对患者进行至少1年的随访。
患者的平均年龄为62.3±10.6岁，女性占43.7%。HALP评分低的组患者的院内死亡率和1年死亡率显著更高（分别为6.0%对2.1%，P = 0.019；22.5%对9.9%，P < 0.001）。在受试者工作特征曲线分析中，HALP评分临界值为34.6时预测1年死亡率的灵敏度为71%，特异度为65%（曲线下面积：0.707，95%置信区间：0.651 - 0.762，P < 0.001）。在Kaplan - Meier分析中，HALP评分较低的组随时间观察到更高的死亡率（对数秩检验 = 16.767，P < 0.001）。在Cox回归分析中，发现HALP评分是1年死亡率的独立预测因素（比值比：0.969，95%置信区间：0.958 - 0.981，P < 0.00）。
我们发现低HALP评分可预测诊断为NSTEMI入院患者的院内死亡率和1年死亡率。
